A Phase 1 study of fb-PMT in recurrent Glioblastoma
Active, Not Recruiting Phase 1 NCT05226494
Study Description
A Clinical Study to Evaluate the Safety and Tolerability of a New Drug (fb-PMT) for the Treatment of Recurrent Brain Cancer
Study Details
- Registry ID:
- NCT05226494
- Conditions:
- Glioma, Malignant
- Phase:
- Phase 1
- Target Enrollment:
- 34 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Study Locations (1 site)
-
Smilow Cancer Hospital
New Haven, Connecticut, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.